Shreya C. Pal

Shreya C. Pal

Auto-generated profile, based on publicly available information

Shreya C. Pal

Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2024 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
MRMariana M. Ramírez-Mejía
Mariana M. Ramírez-Mejía
SCStephany Mercedes Castillo-Castañeda
Stephany Mercedes Castillo-Castañeda
SPShreya C. Pal
Shreya C. Pal
XQXingshun Qi
Xingshun Qi
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez
Bilirubin, the primary breakdown product of hemoproteins, particularly hemoglobin, plays a key role in the diagnosis, prognosis, and monitoring of liver diseases. In acute liver diseases, such as acute liver failure, drug-induced liver injury, and viral hepatitis, bilirubin serves as a biomarker reflecting the extent of hepatocyte loss and liver damage. Chronic liver diseases, including alcohol-related liver disease, chronic hepatitis C virus infection, metabolic dysfunction-associated fatty liver disease, and autoimmune liver diseases, are marked by persistent liver injury and inflammation. Bilirubin levels in chronic liver diseases provide insight into liver function, disease severity, and prognosis. As a versatile biomarker, bilirubin offers valuable information on the pathophysiology of liver diseases and aids in guiding clinical decision-making regarding the treatment of liver diseases and their complications. This review aimed to explore the multifunctional role of bilirubin in liver diseases by analyzing its biological functions beyond its role as a biomarker of liver damage.

26 February 2023 in Clinics in Liver Disease
Verified
Journal Article
Closed access
MCMarlen Ivon Castellanos-Fernandez
Marlen Ivon Castellanos-Fernandez
SPShreya C. Pal
Shreya C. Pal
MAMarco Arrese
Marco Arrese
JAJuan Pablo Arab
Juan Pablo Arab
JGJacob George
Jacob George
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez

8 August 2022 in Medical Science Monitor
Verified
Journal Article
Open access
BBBeatriz Barranco-Fragoso
Beatriz Barranco-Fragoso
SPShreya C. Pal
Shreya C. Pal
LDLuis E. Díaz-Orozco
Luis E. Díaz-Orozco
RDRita Dorantes-Heredia
Rita Dorantes-Heredia
XQXingshun Qi
Xingshun Qi
Nahum Mendez-SanchezNahum Mendez-Sanchez
Nahum Mendez-Sanchez
Metabolic dysfunction-associated fatty liver disease (MAFLD) is now the term used for hepatic steatosis in patients who are overweight or obese, have type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. The prevalence of MAFLD among morbidly obese subjects is 65–93%. Hepatic dendritic cells (hDCs) are antigen-presenting cells that induce T cell-mediated immunity. MAFLD pathogenesis involves numerous immune cell-mediated inflammatory processes, while the particular role of hDCs is yet to be well defined. This study aimed to identify hDCs in liver biopsies from 128 patients with MAFLD associated with obesity. In this cross-sectional study, 128 liver biopsies from 128 patients with MAFLD (diagnosed as presence of hepatic steatosis, plus T2DM, metabolic dysregulation or overweight/obesity) were collected and assessed for CD11c+ immunoreactivity degree (CD11c as dendritic cell biomarker), through antigen retrieval, reaction with CD11c antibodies (primary), and marking with diaminobenzidine chromogen. Among the 128 patients with MAFLD, 64 (50%) had MAFLD and fibrosis and 72 (56.2%) positively expressed hDCs (CD11c+). Among morbidly obese patients, 49 (64.5%) positively expressed hDCs (CD11c+) in liver tissue; from patients with obesity grade I- grade II (GI–II), 18 (54.5%) positively expressed hDCs (CD11c+) in liver tissue; and from non-obese patients with MAFLD, 5 (26.3%) positively expressed hDCs (CD11c+) in liver tissue. hDC expression increases significantly in morbidly obese patients with MAFLD compared with non-obese patients, independent of the degree of fibrosis, suggesting the role of adaptive changes within hDCs in the perpetuation of inflammatory insults in chronic liver diseases.